Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea

Pfizer2,758 enrolled

Overview

The objective of this study is to evaluate the real-world prescription patterns of Palbociclib in breast cancer (BC) patients who were treated with Palbociclib in combination with AI as a 1st line of therapy using the national health insurance claims data in South Korea.

Study Type

OBSERVATIONAL

Enrollment

2,758

Conditions

Metastatic Breast Cancer

Interventions

Patients who received Palbociclib as first line therapy in MBC settingDRUG

Patients who received Palbociclib as first line therapy in MBC setting

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who were prescribed with palbociclib in combination with AI for at least 1 cycle during the index period * Patients who were diagnosed with BC during the index period Exclusion Criteria: * Male * Prescribed with palbociclib during 12-month period preceding the index date

Locations (1)

Pfizer Local Country Office

Seoul, South Korea

Outcomes

Primary Outcomes

Total treatment duration and cycle for Palbociclib

Time frame: From index date (Index date: 06 Nov 2012 to 30 Sep 2020) to the end date of last palbociclib prescription (maximum of 34.8 months from the index date)

Secondary Outcomes

Assessment on dose modification of Palbociclib as first line of therapy in BC patients in real-world setting.

Time frame: From the index date (Index date: 06 Nov 2012 to 30 Sep 2020) to the time of reduction or increase in the dose given in the subsequent Palbociclib prescription (up to 30 Sep 2020)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.